Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06261944
Other study ID # NIRDM-SXCIP03
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date March 13, 2024
Est. completion date August 8, 2024

Study information

Verified date May 2024
Source Glyconics Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main clinical study objective is to confirm the accuracy of the Glyconics-DS spectrometer when used in its intended medical purpose population, i.e., in individuals with unknown diabetes risk. Additionally, this investigation will serve as a pivotal performance evaluation for the associated software for correct delivery of the algorithm-based analysis of the individual diabetes risk. The study will be considered positive if the backend delivery of the chemometrics output is performed correctly as per the cloud-based analysis and its delivery represents the essential medical software to be evaluated in this investigation. The 'true' diabetes risk will be contrasted against values of an internal biomarker indicative of glycaemia, HbA1c, as measured based on standardised, certified methodology.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 486
Est. completion date August 8, 2024
Est. primary completion date May 21, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Apparently healthy adults (=18 years of age) with unknown diabetes status willing to participate in and provide a written consent for the study - Willingness to undertake assisted assessment of glycaemia: by both the NIR spectral measurements in a chosen middle fingernail, and HbA1c (blood sample) - Individuals with at least one visually assessed undamaged, intact (preferably middle) fingernail. Exclusion Criteria: - Individuals with any known medical conditions impacting either of the assessment methodology for glycaemia, such as: - Severe forms of anaemia (diagnosed iron deficiency, sickle cell anaemia or similar). - Haemoglobinopathies or atypical haemoglobin subtypes not detectable by regular (local) laboratory assays for HbA1c. - Severe renal impairment (CKD stage III-IV) or decompensated hepatic disease. - Severe Vitamin D deficiency (diagnosed or measured 25(OH)D3 < 25 nmol/ml). - Known severe immunodeficiency such as HIV, malignancy or other chronic condition significantly impacting assessment of glycaemia. - Eating disorders (as per clinical assessment) - Recent (within 28 days) blood donation - Any other type of known diabetes than T2DM, if diagnosed (T1DM, GDM, MODY, etc.) - Any structural, deviating and visually detectable deviations in the appearance of the (only/ to be assessed) middle fingernail potentially impacting the spectra measurement, including: - nail dystrophy or deformity - severe nail infections (onychomycosis causing visual changes in the appearance of the nail). - rare hereditable conditions impacting the structure of keratin. - mechanical damage or marks on the surface of the nail after removal of nail polish. - use of acrylic or gel nail decoration and polish, which cannot be removed with acetone (use of acetone necessitates a 15 min post-removal wash-out time) - Any systemic or topical medication known to modify either the surface or structure of the nail or accuracy of HbA1c value.

Study Design


Intervention

Device:
Near-infrared (NIR)
Near-infrared assessment of glycated keratin in middle fingernail

Locations

Country Name City State
Spain Sant Pau Hospital Barcelona

Sponsors (1)

Lead Sponsor Collaborator
Glyconics Ltd

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dichotomised diabetes risk status YELLOW: HbA1c value < 48 mmol/mol OR ORANGE: HbA1c value >= 48 mmol/mol. 10 seconds
Secondary Sensitivity and specificity HbA1c cut-off value of 48 mmol/mol (6.5%) and HbA1c cut-off value of 42 mmol/mol (6.0%) 10 seconds
See also
  Status Clinical Trial Phase
Completed NCT04082585 - Total Health Improvement Program Research Project
Enrolling by invitation NCT05367024 - Broccoli Effect on Glycated Haemoglobin (HbA1c) N/A
Withdrawn NCT02400450 - Designer Functional Foods on Parameters of Metabolic and Vascular in Prediabetes N/A
Completed NCT02933424 - Project Plant Protein: the P3 Study in Humans N/A
Completed NCT02656212 - Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin (Part 2) Phase 1
Completed NCT02330276 - Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin Phase 1
Completed NCT01488279 - Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy N/A
Completed NCT00831129 - A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs Phase 2/Phase 3
Completed NCT00536250 - Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth N/A
Recruiting NCT05563090 - Investigating the Syndrome Differentiation of Diabetic and Pre-diabetic Using Digitalized TCM Diagnostic Tools
Active, not recruiting NCT04991142 - Models of Nutrition From Continuous Glucose Monitors
Completed NCT02759055 - Pre-Diabetes Cardiovascular (CV) Care (Pre-Diabetes Wizard) N/A
Completed NCT00775684 - Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass N/A
Completed NCT03695913 - Continuous Glucose Monitoring (CGM) With a Low Carbohydrate Diet to Reduce Weight in Patients With Pre-Diabetes N/A
Completed NCT04051008 - CTSI Pilot: Improving Adherence to Diabetic Diet N/A
Recruiting NCT04897945 - A Shared Decision Making Intervention for Diabetes Prevention in Women With a History of Gestational Diabetes Mellitus N/A
Not yet recruiting NCT04442451 - Mechanisms of Fatigability With Diabetes N/A
Not yet recruiting NCT05925933 - High Protein Diet on Transcriptomic, Metabolomics, Hepatic and Pancreatic Fat Anatomy and Physiology in Asian Indians With Pre-diabetes N/A
Active, not recruiting NCT05654051 - The SLIM LIVER Study Phase 2
Completed NCT02919397 - Motivational Instant Messaging and E-diabetes Prevention Programme for High Risk of Type 2 Diabetes N/A